S&P 500   4,584.92 (+1.15%)
DOW   35,366.17 (+0.96%)
QQQ   372.86 (+1.74%)
AAPL   168.89 (+1.60%)
MSFT   310.26 (+2.28%)
FB   324.65 (+1.58%)
GOOGL   2,740.21 (+1.40%)
AMZN   3,130.61 (+0.15%)
TSLA   1,034.44 (+3.90%)
NVDA   253.95 (+1.31%)
BABA   133.68 (+4.65%)
NIO   30.41 (+6.22%)
AMD   127.92 (-0.27%)
CGC   7.99 (+4.58%)
MU   89.49 (-0.57%)
GE   100.91 (+0.29%)
T   27.35 (+0.26%)
F   22.27 (-0.80%)
DIS   151.24 (+0.75%)
AMC   19.20 (+4.80%)
PFE   54.05 (+0.95%)
ACB   5.03 (+3.50%)
BA   220.76 (+1.70%)
S&P 500   4,584.92 (+1.15%)
DOW   35,366.17 (+0.96%)
QQQ   372.86 (+1.74%)
AAPL   168.89 (+1.60%)
MSFT   310.26 (+2.28%)
FB   324.65 (+1.58%)
GOOGL   2,740.21 (+1.40%)
AMZN   3,130.61 (+0.15%)
TSLA   1,034.44 (+3.90%)
NVDA   253.95 (+1.31%)
BABA   133.68 (+4.65%)
NIO   30.41 (+6.22%)
AMD   127.92 (-0.27%)
CGC   7.99 (+4.58%)
MU   89.49 (-0.57%)
GE   100.91 (+0.29%)
T   27.35 (+0.26%)
F   22.27 (-0.80%)
DIS   151.24 (+0.75%)
AMC   19.20 (+4.80%)
PFE   54.05 (+0.95%)
ACB   5.03 (+3.50%)
BA   220.76 (+1.70%)
S&P 500   4,584.92 (+1.15%)
DOW   35,366.17 (+0.96%)
QQQ   372.86 (+1.74%)
AAPL   168.89 (+1.60%)
MSFT   310.26 (+2.28%)
FB   324.65 (+1.58%)
GOOGL   2,740.21 (+1.40%)
AMZN   3,130.61 (+0.15%)
TSLA   1,034.44 (+3.90%)
NVDA   253.95 (+1.31%)
BABA   133.68 (+4.65%)
NIO   30.41 (+6.22%)
AMD   127.92 (-0.27%)
CGC   7.99 (+4.58%)
MU   89.49 (-0.57%)
GE   100.91 (+0.29%)
T   27.35 (+0.26%)
F   22.27 (-0.80%)
DIS   151.24 (+0.75%)
AMC   19.20 (+4.80%)
PFE   54.05 (+0.95%)
ACB   5.03 (+3.50%)
BA   220.76 (+1.70%)
S&P 500   4,584.92 (+1.15%)
DOW   35,366.17 (+0.96%)
QQQ   372.86 (+1.74%)
AAPL   168.89 (+1.60%)
MSFT   310.26 (+2.28%)
FB   324.65 (+1.58%)
GOOGL   2,740.21 (+1.40%)
AMZN   3,130.61 (+0.15%)
TSLA   1,034.44 (+3.90%)
NVDA   253.95 (+1.31%)
BABA   133.68 (+4.65%)
NIO   30.41 (+6.22%)
AMD   127.92 (-0.27%)
CGC   7.99 (+4.58%)
MU   89.49 (-0.57%)
GE   100.91 (+0.29%)
T   27.35 (+0.26%)
F   22.27 (-0.80%)
DIS   151.24 (+0.75%)
AMC   19.20 (+4.80%)
PFE   54.05 (+0.95%)
ACB   5.03 (+3.50%)
BA   220.76 (+1.70%)
NASDAQ:KZIA

Kazia Therapeutics Stock Forecast, Price & News

$7.43
-0.49 (-6.19%)
(As of 01/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.43
$8.28
50-Day Range
$7.35
$11.60
52-Week Range
$6.89
$14.89
Volume
43,363 shs
Average Volume
14,040 shs
Market Capitalization
$98.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.44
30 days | 90 days | 365 days | Advanced Chart
Receive KZIA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Kazia Therapeutics logo

About Kazia Therapeutics

Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Headlines

Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Update
January 15, 2022 |  americanbankingnews.com
GBM AGILE Opens to Paxalisib in Canada
November 29, 2021 |  finance.yahoo.com
PNOC Study in Childhood Brain Cancer Enrols First Patient
November 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZIA
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
$11.35 million
Book Value
$2.14 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
13,069,000
Market Cap
$98.08 million
Optionable
Not Optionable

Company Calendar

Today
1/20/2022
Fiscal Year End
6/30/2022

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

1055th out of 1,415 stocks

Pharmaceutical Preparations Industry

513th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Kazia Therapeutics (NASDAQ:KZIA) Frequently Asked Questions

Is Kazia Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kazia Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kazia Therapeutics stock.
View analyst ratings for Kazia Therapeutics
or view top-rated stocks.

How has Kazia Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Kazia Therapeutics' stock was trading at $3.98 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KZIA stock has increased by 86.7% and is now trading at $7.43.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Kazia Therapeutics?

Kazia Therapeutics saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 3,100 shares, a decrease of 59.2% from the December 15th total of 7,600 shares. Based on an average daily trading volume, of 27,800 shares, the short-interest ratio is presently 0.1 days.
View Kazia Therapeutics' Short Interest
.

What price target have analysts set for KZIA?

1 Wall Street analysts have issued twelve-month price objectives for Kazia Therapeutics' stock. Their forecasts range from $18.00 to $18.00. On average, they expect Kazia Therapeutics' stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 142.3% from the stock's current price.
View analysts' price targets for Kazia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the following people:
  • James Garner, Chief Executive Officer, Executive Director & MD
  • Gabrielle Heaton, Director-Finance & Administration
  • John E. Friend, Chief Medical Officer
  • Catherine Hill, Secretary

What other stocks do shareholders of Kazia Therapeutics own?

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

How do I buy shares of Kazia Therapeutics?

Shares of KZIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $7.43.

How much money does Kazia Therapeutics make?

Kazia Therapeutics has a market capitalization of $98.08 million and generates $11.35 million in revenue each year.

How many employees does Kazia Therapeutics have?

Kazia Therapeutics employs 2,021 workers across the globe.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is www.kaziatherapeutics.com.

Where are Kazia Therapeutics' headquarters?

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company can be reached via phone at (129) 472-4101, via email at [email protected], or via fax at 61-2-9476-0388.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.